68 related articles for article (PubMed ID: 11584356)
1. Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles.
Wiencke K; Spurkland A; Schrumpf E; Boberg KM
Hepatology; 2001 Oct; 34(4 Pt 1):625-30. PubMed ID: 11584356
[TBL] [Abstract][Full Text] [Related]
2. Complete MHC haplotype sequencing for common disease gene mapping.
Stewart CA; Horton R; Allcock RJ; Ashurst JL; Atrazhev AM; Coggill P; Dunham I; Forbes S; Halls K; Howson JM; Humphray SJ; Hunt S; Mungall AJ; Osoegawa K; Palmer S; Roberts AN; Rogers J; Sims S; Wang Y; Wilming LG; Elliott JF; de Jong PJ; Sawcer S; Todd JA; Trowsdale J; Beck S
Genome Res; 2004 Jun; 14(6):1176-87. PubMed ID: 15140828
[TBL] [Abstract][Full Text] [Related]
3. Proteome-wide Mendelian randomization highlights AIF1 and HLA-DQA2 as targets for primary sclerosing cholangitis.
Chen L; Zhao Y; Li M; Lv G
Hepatol Int; 2024 Apr; 18(2):517-528. PubMed ID: 37950809
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough of solid tumor treatment: CAR-NK immunotherapy.
Wang W; Liu Y; He Z; Li L; Liu S; Jiang M; Zhao B; Deng M; Wang W; Mi X; Sun Z; Ge X
Cell Death Discov; 2024 Jan; 10(1):40. PubMed ID: 38245520
[TBL] [Abstract][Full Text] [Related]
5. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis.
Kim YS; Hurley EH; Park Y; Ko S
Exp Mol Med; 2023 Jul; 55(7):1380-1387. PubMed ID: 37464092
[TBL] [Abstract][Full Text] [Related]
6. Study of the association between a
Abdel-Rahman AA; Farag MAH; Naguib M; Abdelsameea E; Abdel-Bary HM
Clin Exp Hepatol; 2022 Dec; 8(4):293-299. PubMed ID: 36683874
[TBL] [Abstract][Full Text] [Related]
7. Decreased CD57 expression of natural killer cells enhanced cytotoxicity in patients with primary sclerosing cholangitis.
Liu B; Yang GX; Sun Y; Tomiyama T; Zhang W; Leung PSC; He XS; Dhaliwal S; Invernizzi P; Gershwin ME; Bowlus CL
Front Immunol; 2022; 13():912961. PubMed ID: 36059513
[TBL] [Abstract][Full Text] [Related]
8. Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Review.
Da Cunha T; Vaziri H; Wu GY
J Clin Transl Hepatol; 2022 Jun; 10(3):531-542. PubMed ID: 35836773
[TBL] [Abstract][Full Text] [Related]
9. NK Cells in Autoimmune Diseases: Protective or Pathogenic?
Liu M; Liang S; Zhang C
Front Immunol; 2021; 12():624687. PubMed ID: 33777006
[TBL] [Abstract][Full Text] [Related]
10. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis.
Tornai T; Palyu E; Vitalis Z; Tornai I; Tornai D; Antal-Szalmas P; Norman GL; Shums Z; Veres G; Dezsofi A; Par G; Par A; Orosz P; Szalay F; Lakatos PL; Papp M
World J Gastroenterol; 2017 Aug; 23(29):5412-5421. PubMed ID: 28839442
[TBL] [Abstract][Full Text] [Related]
11. Genetics of primary sclerosing cholangitis and pathophysiological implications.
Jiang X; Karlsen TH
Nat Rev Gastroenterol Hepatol; 2017 May; 14(5):279-295. PubMed ID: 28293027
[TBL] [Abstract][Full Text] [Related]
12. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis.
Goyette P; Boucher G; Mallon D; Ellinghaus E; Jostins L; Huang H; Ripke S; Gusareva ES; Annese V; Hauser SL; Oksenberg JR; Thomsen I; Leslie S; ; ; ; ; ; ; ; ; Daly MJ; Van Steen K; Duerr RH; Barrett JC; McGovern DP; Schumm LP; Traherne JA; Carrington MN; Kosmoliaptsis V; Karlsen TH; Franke A; Rioux JD
Nat Genet; 2015 Feb; 47(2):172-9. PubMed ID: 25559196
[TBL] [Abstract][Full Text] [Related]
13. Refinement of the MHC risk map in a scandinavian primary sclerosing cholangitis population.
Næss S; Lie BA; Melum E; Olsson M; Hov JR; Croucher PJ; Hampe J; Thorsby E; Bergquist A; Traherne JA; Schrumpf E; Boberg KM; Schreiber S; Franke A; Karlsen TH
PLoS One; 2014; 9(12):e114486. PubMed ID: 25521205
[TBL] [Abstract][Full Text] [Related]
14. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.
Tsaitas C; Semertzidou A; Sinakos E
World J Hepatol; 2014 Apr; 6(4):178-87. PubMed ID: 24799986
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of primary sclerosing cholangitis.
Pollheimer MJ; Halilbasic E; Fickert P; Trauner M
Best Pract Res Clin Gastroenterol; 2011 Dec; 25(6):727-39. PubMed ID: 22117638
[TBL] [Abstract][Full Text] [Related]
16. Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis.
Hov JR; Kosmoliaptsis V; Traherne JA; Olsson M; Boberg KM; Bergquist A; Schrumpf E; Bradley JA; Taylor CJ; Lie BA; Trowsdale J; Karlsen TH
Hepatology; 2011 Jun; 53(6):1967-76. PubMed ID: 21413052
[TBL] [Abstract][Full Text] [Related]
17. Cutting edge issues in primary sclerosing cholangitis.
Bowlus CL
Clin Rev Allergy Immunol; 2011 Oct; 41(2):139-50. PubMed ID: 21170605
[TBL] [Abstract][Full Text] [Related]
18. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.
Bowlus CL; Li CS; Karlsen TH; Lie BA; Selmi C
Liver Transpl; 2010 Nov; 16(11):1324-30. PubMed ID: 21031548
[TBL] [Abstract][Full Text] [Related]
19. The immunobiology of primary sclerosing cholangitis.
Aron JH; Bowlus CL
Semin Immunopathol; 2009 Sep; 31(3):383-97. PubMed ID: 19468733
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell receptors and their ligands in liver diseases.
Yamagiwa S; Kamimura H; Ichida T
Med Mol Morphol; 2009 Mar; 42(1):1-8. PubMed ID: 19294486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
